Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011

Creator(s)

Daniel C. Payne, National Center for Immunization and Respiratory Diseases
Julie A. Boom, Texas Children's Hospital
Mary Allen Staat, University of Cincinnati College of Medicine
Kathryn M. Edwards, Vanderbilt University Medical Center
Peter G. Szilagyi, University of Rochester School of Medicine and Dentistry
Eileen J. Klein, Seattle Children's Hospital
Rangaraj Selvarangan, Children's Mercy HospitalFollow
Parvin H. Azimi, UCSF Benioff Children's Hospital Oakland
Christopher J. Harrison, Children's Mercy HospitalFollow
Mary Moffatt, Children's Mercy HospitalFollow
Samantha H. Johnston, UCSF Benioff Children's Hospital Oakland
Leila C. Sahni, Texas Children's Hospital
Carol J, Baker, Texas Children's Hospital
Marcia A. Rench, Texas Children's Hospital
Stephanie Donauer, University of Cincinnati College of Medicine
Monica McNeal, University of Cincinnati College of Medicine
James Chappell, Vanderbilt University Medical Center
Geoffrey A. Weinberg, University of Rochester School of Medicine and Dentistry
Azadeh Tasslimi, Washington State Department of Health
Jacqueline E. Tate, National Center for Immunization and Respiratory Diseases
Mary Wikswo, National Center for Immunization and Respiratory Diseases
Aaron T. Curns, National Center for Immunization and Respiratory Diseases
Iddrisu Sulemana, National Center for Immunization and Respiratory Diseases
Slavica Mijatovic-Rustempasic, National Center for Immunization and Respiratory Diseases
Mathew D. Esona, National Center for Immunization and Respiratory Diseases
Michael D. Bowen, National Center for Immunization and Respiratory Diseases
Jon R. Gentsch, National Center for Immunization and Respiratory Diseases
Umesh D. Parashar, National Center for Immunization and Respiratory Diseases

Document Type

Article

Publication Date

7-2013

Identifier

DOI: 10.1093/cid/cit164; PMCID: PMC4618548

Abstract

Background We assessed vaccine effectiveness (VE) for RotaTeq (RV5; 3 doses) and Rotarix (RV1; 2 doses) at reducing rotavirus acute gastroenteritis (AGE) inpatient and emergency department (ED) visits in US children.

Methods We enrolled children vaccine, age, ethnicity, genotype, and clinical setting.

Results RV5-specific analyses included 359 rotavirus cases and 1811 rotavirus-negative AGE controls. RV1-specific analyses included 60 rotavirus cases and 155 rotavirus-negative AGE controls. RV5 and RV1 were 84% (95% confidence interval [CI], 78%-88%) and 70% (95% CI, 39%-86%) effective, respectively, against rotavirus-associated ED visits and hospitalizations combined. By clinical setting, RV5 VE against ED and inpatient rotavirus-associated visits was 81% (95% CI, 70%-84%) and 86% (95% CI, 74%-91%), respectively. RV1 was 78% (95% CI, 46%-91%) effective against ED rotavirus disease; study power was insufficient to evaluate inpatient RV1 VE. No waning of immunity was evident during the first 4 years of life for RV5, nor during the first 2 years of life for RV1. RV5 provided genotype-specific protection against each of the predominant strains (G1P[8], G2P[4], G3P[8], G12P[8]), while RV1 VE was statistically significant for the most common genotype, G3P[8].

Conclusions Both RV5 and RV1 significantly protected against medically attended rotavirus gastroenteritis in this real-world assessment. © 2013 The Author.

Journal Title

Clinical Infectious Diseases

Volume

57

Issue

1

First Page

13

Last Page

20

Keywords

New Vaccine Surveillance Network, RotaTeq, rotavirus, vaccine

Comments

Grant support

• CC999999/Intramural CDC HHS/United States

Recommended Citation

Payne, D. C., Boom, J. A., Staat, M., Edwards, K. M., Szilagyi, P. G., Klein, E. J., Selvarangan, R., Azimi, P. H., Harrison, C. J., Moffatt, M., Johnston, S. H., Sahni, L. C., Baker, C. J., Rench, M. A., Donauer, S., McNeal, M., Chappell, J., Weinberg, G. A., Tasslimi, A., Tate, J. E., Wikswo, M., Curns, A. T., Sulemana, I., Mijatovic-Rustempasic, S., Esona, M. D., Bowen, M. D., Gentsch, J. R., Parashar, U. D. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of>age, 2009-2011 Clinical Infectious Diseases 57, 13-20 (2013).